Specialty Chemicals Expansion Will Capture Global Supply Trends

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

15 Dec 24

Updated

03 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-44.1%

7D

0.4%

Loading

1Y

-44.1%

7D

0.4%

You can edit this narrative until Dec 4 3:10 AM. Then, changes will post as Updates.

Author's Valuation

₹1.84k17.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 03 Dec 25

Fair value Decreased 0.65%

506401: Upcoming Board Review Will Highlight Stronger Margins And Revenue Outlook

Analysts have slightly trimmed their price target on Deepak Nitrite to Rs 1,843 from Rs 1,856, reflecting a marginally higher discount rate despite incrementally stronger assumptions for revenue growth and profit margins. What's in the News Board meeting scheduled for November 12, 2025, at 14:30 IST to review and approve standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025 (company filing) Limited review report from Deloitte Haskins and Sells LLP to be considered in compliance with Regulation 33 of the listing regulations (company filing) Board will also deliberate on other business matters alongside the financial review agenda (company filing) Valuation Changes Fair Value Estimate has fallen slightly to ₹1,843.53 from ₹1,855.59, reflecting a modest downward revision in intrinsic value.

Shared on 19 Nov 25

Fair value Decreased 5.26%

506401: Upcoming Board Review Will Address Key Financial Chart Points

Analysts have revised Deepak Nitrite's fair value estimate downward from ₹1,958.71 to ₹1,855.59. This change reflects updated assumptions about the company's future growth and market environment.

Shared on 19 Aug 25

Fair value Decreased 8.10%

Despite a stronger revenue growth outlook, Deepak Nitrite's consensus price target was revised downward to ₹2013 primarily due to a decline in net profit margin. What's in the News Board meeting scheduled to approve Q1 FY26 standalone and consolidated unaudited financial results.

Shared on 01 May 25

Fair value Decreased 0.047%

Shared on 23 Apr 25

Fair value Decreased 0.017%

Shared on 17 Apr 25

Fair value Decreased 0.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.86%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.49%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 0.16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 1.24%

AnalystConsensusTarget has decreased revenue growth from 16.6% to 9.3% and increased discount rate from 13.2% to 14.6%.

AnalystConsensusTarget Fair Value

₹1.84k

17.1% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

13.21%

Chemicals revenue growth rate

0.62%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

13.48%

Calculation

₹11.31b

Earnings '28

x

32.19x

PE Ratio '28

=

₹364.04b

Market Cap '28

₹364.04b

Market Cap '28

/

135.89m

No. shares '28

=

₹2.68k

Share Price '28

₹2.68k Share Price '28

Discounted to 2025 @ 13.51% p.a.

=

₹1.83k

Fair Value '25